BFM
DMAAR

Boothbay Fund Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Boothbay Fund Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42K Buy
695,227
+125,227
+22% +$13.3K ﹤0.01% 1934
2025
Q4 		$107K Hold
570,000
– – ﹤0.01% 1733
2025
Q3 		$124K Hold
570,000
– – ﹤0.01% 1709
2025
Q2 		$68.5K Buy
+570,000
New +$73.3K ﹤0.01% 1333

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Boothbay Fund Management's DMAAR Position: Q1 2026 in Review

Boothbay Fund Management increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 22% in Q1 2026, buying an estimated $13.3K and bringing the position to 695,227 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #1934.

Boothbay Fund Management first reported a position in DMAAR in Q2 2025 and has held it in 4 quarters since. The position peaked at $124K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Boothbay Fund Management held 695,227 shares of Drugs Made In America Acquisition Corp Rights worth $42K as of Q1 2026.
  • Boothbay Fund Management bought 125,227 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $13.3K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1934 holding.
  • Boothbay Fund Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q2 2025 and has held it in 4 quarters since.
  • Boothbay Fund Management's Drugs Made In America Acquisition Corp Rights position peaked at $124K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.